Edwards Lifesciences Corporation (BVMF:E1WL34)

Market Cap	258.44B
Revenue (ttm)	31.36B
Net Income (ttm)	7.29B
Shares Out	n/a
EPS (ttm)	12.42
PE Ratio	35.45
Forward PE	30.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	137
Average Volume	156
Open	111.76
Previous Close	112.75
Day's Range	111.76 - 111.86
52-Week Range	98.15 - 117.36
Beta	0.97
RSI	49.92
Earnings Date	Feb 13, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: E1WL34

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD